Uprifosbuvir
Based on 1 Customer Validation
Uprifosbuvir (IDX21437; MK-3682) is a nucleotide analog inhibitor that inhibits YFV NS5 RNA-dependent RNA polymerase (RNA polymerase) and HCV NS5b. Uprifosbuvir can be used for research on yellow fever and chronic hepatitis C virus (HCV) infection.
For research use only. We do not sell to patients.
- Purity : 98.17%
- CAS No.: 1496551-77-9
- Formula: C22H29ClN3O9P
- Molecular Weight:545.91
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Huh-7.5 | EC50 |
1.1 μM
|
Antiviral activity against YFV 17D original in human hepatoma Huh7.5 cells assessed by virus antigen quantification after 72 hrs incubation.
Antiviral activity against YFV 17D original in human hepatoma Huh7.5 cells assessed by virus antigen quantification after 72 hrs incubation.
|
41765050 |
| Huh-7.5 | EC50 |
9.5 μM
|
Antiviral activity against YFV 17D variant YFV-sof in human hepatoma Huh7.5 cells assessed by virus antigen quantification after 72 hrs incubation.
Antiviral activity against YFV 17D variant YFV-sof in human hepatoma Huh7.5 cells assessed by virus antigen quantification after 72 hrs incubation.
|
41765050 |
| Huh-7.5 | EC50 |
11.9 μM
|
Antiviral activity against YFV 17D variant YFV-upr in human hepatoma Huh7.5 cells assessed by virus antigen quantification after 72 hrs incubation.
Antiviral activity against YFV 17D variant YFV-upr in human hepatoma Huh7.5 cells assessed by virus antigen quantification after 72 hrs incubation.
|
41765050 |
| Huh-7.5 | EC50 |
2.1 μM
|
Antiviral activity against YFV 17D reverse-engineered NS5 mutant YFV^M478K in human hepatoma Huh7.5 cells assessed by virus antigen quantification after 72 hrs incubation.
Antiviral activity against YFV 17D reverse-engineered NS5 mutant YFV^M478K in human hepatoma Huh7.5 cells assessed by virus antigen quantification after 72 hrs incubation.
|
41765050 |
| Huh-7.5 | EC50 |
5.9 μM
|
Antiviral activity against YFV 17D reverse-engineered NS5 mutant YFV^A482G in human hepatoma Huh7.5 cells assessed by virus antigen quantification after 72 hrs incubation.
Antiviral activity against YFV 17D reverse-engineered NS5 mutant YFV^A482G in human hepatoma Huh7.5 cells assessed by virus antigen quantification after 72 hrs incubation.
|
41765050 |
| Huh-7.5 | EC50 |
12.4 μM
|
Antiviral activity against YFV 17D reverse-engineered NS5 double mutant YFV^M478K+A482G in human hepatoma Huh7.5 cells assessed by virus antigen quantification after 72 hrs incubation.
Antiviral activity against YFV 17D reverse-engineered NS5 double mutant YFV^M478K+A482G in human hepatoma Huh7.5 cells assessed by virus antigen quantification after 72 hrs incubation.
|
41765050 |
| Huh-7.5 | EC50 |
1.2 μM
|
Antiviral activity against YFV 17D reverse-engineered NS5 mutant YFV^V360L in human hepatoma Huh7.5 cells assessed by virus antigen quantification after 72 hrs incubation.
Antiviral activity against YFV 17D reverse-engineered NS5 mutant YFV^V360L in human hepatoma Huh7.5 cells assessed by virus antigen quantification after 72 hrs incubation.
|
41765050 |
| Huh-7.5 | EC50 |
2.6 μM
|
Antiviral activity against YFV 17D reverse-engineered NS5 mutant YFV^V607I in human hepatoma Huh7.5 cells assessed by virus antigen quantification after 72 hrs incubation.
Antiviral activity against YFV 17D reverse-engineered NS5 mutant YFV^V607I in human hepatoma Huh7.5 cells assessed by virus antigen quantification after 72 hrs incubation.
|
41765050 |
| Huh-7.5 | EC50 |
1.4 μM
|
Antiviral activity against YFV 17D reverse-engineered NS5 double mutant YFV^V360L+V607I in human hepatoma Huh7.5 cells assessed by virus antigen quantification after 72 hrs incubation.
Antiviral activity against YFV 17D reverse-engineered NS5 double mutant YFV^V360L+V607I in human hepatoma Huh7.5 cells assessed by virus antigen quantification after 72 hrs incubation.
|
41765050 |
| Huh-7.5 | EC50 |
1.6 μM
|
Antiviral activity against YFV 17D reverse-engineered NS5 mutant YFV^L720M in human hepatoma Huh7.5 cells assessed by virus antigen quantification after 72 hrs incubation.
Antiviral activity against YFV 17D reverse-engineered NS5 mutant YFV^L720M in human hepatoma Huh7.5 cells assessed by virus antigen quantification after 72 hrs incubation.
|
41765050 |
| Huh-7.5 | EC50 |
10.8 μM
|
Antiviral activity against YFV 17D reverse-engineered NS5 triple mutant YFV^M478K+A482G+L720M in human hepatoma Huh7.5 cells assessed by virus antigen quantification after 72 hrs incubation.
Antiviral activity against YFV 17D reverse-engineered NS5 triple mutant YFV^M478K+A482G+L720M in human hepatoma Huh7.5 cells assessed by virus antigen quantification after 72 hrs incubation.
|
41765050 |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1496551-77-9
-
Appearance Solid
-
Molecular Weight 545.91
-
Formula C22H29ClN3O9P
-
Color White to off-white
-
SMILES
C[C@]([C@@](N(C=CC1=O)C(N1)=O)([H])O[C@@H]2CO[P@@](OC3=CC=CC=C3)(N[C@H](C)C(OC(C)C)=O)=O)([C@@H]2O)Cl
-
Synonyms
IDX21437; MK-3682
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 250 mg/mL (457.95 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Binderup A, et al. Substitutions M478K and A482G in the polymerase of yellow fever virus confer resistance to sofosbuvir and uprifosbuvir in vitro. Antiviral research. 2026 May;249:106381. [Content Brief]
[2]. Klapars A, et al. Efficient synthesis of antiviral agent uprifosbuvir enabled by new synthetic methods. Chemical science. 2021 Jul 07;12(26):9031-9036. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8318 mL | 9.1590 mL | 18.3180 mL | 45.7951 mL |
| 5 mM | 0.3664 mL | 1.8318 mL | 3.6636 mL | 9.1590 mL | |
| 10 mM | 0.1832 mL | 0.9159 mL | 1.8318 mL | 4.5795 mL | |
| 15 mM | 0.1221 mL | 0.6106 mL | 1.2212 mL | 3.0530 mL | |
| 20 mM | 0.0916 mL | 0.4580 mL | 0.9159 mL | 2.2898 mL | |
| 25 mM | 0.0733 mL | 0.3664 mL | 0.7327 mL | 1.8318 mL | |
| 30 mM | 0.0611 mL | 0.3053 mL | 0.6106 mL | 1.5265 mL | |
| 40 mM | 0.0458 mL | 0.2290 mL | 0.4580 mL | 1.1449 mL | |
| 50 mM | 0.0366 mL | 0.1832 mL | 0.3664 mL | 0.9159 mL | |
| 60 mM | 0.0305 mL | 0.1527 mL | 0.3053 mL | 0.7633 mL | |
| 80 mM | 0.0229 mL | 0.1145 mL | 0.2290 mL | 0.5724 mL | |
| 100 mM | 0.0183 mL | 0.0916 mL | 0.1832 mL | 0.4580 mL |
Uprifosbuvir Related Classifications
HY-103487 Related Classifications
Powered by Bioz